Clinical Trial Update: Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports that the Phase 1/2 study of QAX576 for adults with moderate persistent allergic asthma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• QAX576

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 1, Phase 2 | Status: WITHDRAWN